• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Lancet Healthy Longev . Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in

tetano

Editor, Senior Moderator
Lancet Healthy Longev


. 2021 Dec;2(12):e811-e819.
doi: 10.1016/S2666-7568(21)00253-1. Epub 2021 Dec 1.
Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England


Anna Jeffery-Smith[SUP] 1 2 [/SUP], Thomas A J Rowland[SUP] 1 [/SUP], Monika Patel[SUP] 1 [/SUP], Heather Whitaker[SUP] 3 [/SUP], Nalini Iyanger[SUP] 4 [/SUP], Sarah V Williams[SUP] 4 [/SUP], Rebecca Giddings[SUP] 4 [/SUP], Leah Thompson[SUP] 4 [/SUP], Maria Zavala[SUP] 5 [/SUP], Felicity Aiano[SUP] 5 [/SUP], Joanna Ellis[SUP] 5 [/SUP], Angie Lackenby[SUP] 1 [/SUP], Katja Höschler[SUP] 1 [/SUP], Kevin Brown[SUP] 5 [/SUP], Mary E Ramsay[SUP] 5 [/SUP], Robin Gopal[SUP] 1 [/SUP], J Yimmy Chow[SUP] 4 [/SUP], Shamez N Ladhani[SUP] 5 6 [/SUP], Maria Zambon[SUP] 1 [/SUP]



Affiliations
Free PMC article

Abstract

Background: Understanding the duration of protection and risk of reinfection after natural infection is crucial to planning COVID-19 vaccination for at-risk groups, including care home residents, particularly with the emergence of more transmissible variants. We report on the duration, neutralising activity, and protection against the alpha variant of previous SARS-CoV-2 infection in care home residents and staff infected more than 6 months previously.
Methods: We did this prospective observational cohort surveillance in 13 care homes in Greater London, England. All staff and residents were included. Staff and residents had regular nose and throat screening for SARS-CoV-2 by RT-PCR according to national guidelines, with ad hoc testing of symptomatic individuals. From January, 2021, antigen lateral flow devices were also used, but positive tests still required RT-PCR confirmation. Staff members took the swab samples for themselves and the residents. The primary outcome was SARS-CoV-2 RT-PCR positive primary infection or reinfection in previously infected individuals, as determined by previous serological testing and screening or diagnostic RT-PCR results. Poisson regression and Cox proportional hazards models were used to estimate protective effectiveness of previous exposure. SARS-CoV-2 spike, nucleoprotein, and neutralising antibodies were assessed at multiple timepoints as part of the longitudinal follow-up.
Findings: Between April 10 and Aug 3, 2020, we recruited and tested 1625 individuals (933 staff and 692 residents). 248 participants were lost to follow-up (123 staff and 125 residents) and 1377 participants were included in the follow-up period to Jan 31, 2021 (810 staff and 567 residents). There were 23 reinfections (ten confirmed, eight probable, five possible) in 656 previously infected individuals (366 staff and 290 residents), compared with 165 primary infections in 721 susceptible individuals (444 staff and 277 residents). Those with confirmed reinfections had no or low neutralising antibody concentration before reinfection, with boosting of titres after reinfection. Kinetics of binding and neutralising antibodies were similar in older residents and younger staff.
Interpretation: SARS-CoV-2 reinfections were rare in older residents and younger staff. Protection from SARS-CoV-2 was sustained for longer than 9 months, including against the alpha variant. Reinfection was associated with no or low neutralising antibody before reinfection, but significant boosting occurred on reinfection.
 
Back
Top Bottom